Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,600
Total Claims
$1.1M
Drug Cost
556
Beneficiaries
$1,936
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-95%
Opioid rate vs peers
0.1% vs 2.6% avg
+81%
Cost per patient vs peers
$1,936 vs $1,068 avg
+63%
Brand preference vs peers
14.6% vs 9.0% avg
Opioid Prescribing
0.1%
Opioid Rate
11
Opioid Claims
$109
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,251 claims · $847K
Generic: 7,301 claims · $227K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 209 | $107K |
| Sitagliptin Phos/Metformin Hcl | 107 | $104K |
| Teriparatide | 14 | $62K |
| Semaglutide | 48 | $61K |
| Dulaglutide | 18 | $37K |
| Sitagliptin Phos/Metformin Hcl | 29 | $37K |
| Rivaroxaban | 47 | $28K |
| Sitagliptin Phosphate | 30 | $26K |
| Icosapent Ethyl | 73 | $23K |
| Dapagliflozin Propanediol | 12 | $22K |
| Icosapent Ethyl | 32 | $18K |
| Ezetimibe | 331 | $15K |
| Fluticasone/Umeclidin/Vilanter | 28 | $14K |
| Linagliptin/Metformin Hcl | 12 | $13K |
| Linagliptin | 12 | $13K |
Prescribing Profile
Patient Profile
76
Avg Age
58%
Female
1.24
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data